Barclays analyst Gena Wang maintains $Sarepta Therapeutics (SRPT.US)$ with a buy rating, and maintains the target price at $209.
According to TipRanks data, the analyst has a success rate of 42.1% and a total average return of 8.1% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Sarepta Therapeutics (SRPT.US)$'s main analysts recently are as follows:
The company's Q3 results significantly exceeded expectations with impressive revenues for both total and Elevidys. Despite the company's maintained guidance for Elevidys, it is perceived as somewhat cautious.
Sarepta's sales of Elevidys and exon-skipping franchise exceeded market expectations, and the company's outlook for Q4 Elevidys remains strong, potentially leading to additional positive results, provided there is limited impact from the holiday season. There exists a possibility for an increase in the FY25 guidance come January, although current market valuations reflect a perception of the franchise having a five-year trajectory until the exclusivity is lost.
Sales of Elevidys exhibited growth surpassing expectations in Q3, accompanied by optimistic remarks from management regarding the product's launch. It is believed that all indicators are suggestive of Elevidys' potential to become a product generating several billions in revenue, which could be further enhanced by a series of gene therapy introductions anticipated over the ensuing five years.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
巴克萊銀行分析師Gena Wang維持$Sarepta Therapeutics (SRPT.US)$買入評級，維持目標價209美元。
根據TipRanks數據顯示，該分析師近一年總勝率為42.1%，總平均回報率為8.1%。
此外，綜合報道，$Sarepta Therapeutics (SRPT.US)$近期主要分析師觀點如下：
公司的第三季度業績顯著超出預期，無論是總體還是Elevidys的營業收入都表現出色。儘管公司對Elevidys的展望保持謹慎，但受到一定程度的認可。
Sarepta的Elevidys銷售額和exon-skipping特許經營權均超出市場預期，公司對第四季度Elevidys的展望仍然強勁，可能會帶來額外的積極結果，前提是假日季節對其影響有限。存在一種可能性，即到了一月份，FY25的展望可能會有所增加，儘管當前市場估值反映了該特許經營權在失去獨家經營權之前有五年的軌跡。
第三季度Elevidys的銷售表現出超出預期的增長，管理層對產品上市發表了樂觀的言論。人們相信一切跡象都表明Elevidys有潛力成爲一個創造數十億營業收入的產品，這可能會得到進一步增加，因爲預計在接下來的五年中會推出一系列基因治療產品。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
